Elder Pharmaceuticals is targeting revenues of up to one billion dollars from the lucrative $ 70 billion Japanese pharma market. The company has recently received accreditation from Ministry of Health, Japan for its active pharmaceutical ingredients (API) plant at Patalganga and is planning to be an API and advanced intermediate supplier to the Japanese market.
It has already filed for new patents in these markets and expects the approvals in next six months. The company has also developed two products going off patent in the Japanese market in 2014. One of the products is from the CNS category and the second is from the GI segment. Japan is increasing the share of its healthcare spend on generics pharma and is targeting this share to go up to 30 per cent of its total market by 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: